Development of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuum
Abstract Background Dementia prevalence is predicted to triple to 152 million globally by 2050. Alzheimer’s disease (AD) constitutes 70% of cases. There is an urgent need to identify individuals with preclinical AD, a 10–20-year period of progressive brain pathology without noticeable cognitive symp...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-04-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-024-03609-z |
| _version_ | 1797199337347874816 |
|---|---|
| author | Jane Alty Lynette R. Goldberg Eddy Roccati Katherine Lawler Quan Bai Guan Huang Aidan D Bindoff Renjie Li Xinyi Wang Rebecca J. St George Kaylee Rudd Larissa Bartlett Jessica M. Collins Mimieveshiofuo Aiyede Nadeeshani Fernando Anju Bhagwat Julia Giffard Katharine Salmon Scott McDonald Anna E. King James C. Vickers |
| author_facet | Jane Alty Lynette R. Goldberg Eddy Roccati Katherine Lawler Quan Bai Guan Huang Aidan D Bindoff Renjie Li Xinyi Wang Rebecca J. St George Kaylee Rudd Larissa Bartlett Jessica M. Collins Mimieveshiofuo Aiyede Nadeeshani Fernando Anju Bhagwat Julia Giffard Katharine Salmon Scott McDonald Anna E. King James C. Vickers |
| author_sort | Jane Alty |
| collection | DOAJ |
| description | Abstract Background Dementia prevalence is predicted to triple to 152 million globally by 2050. Alzheimer’s disease (AD) constitutes 70% of cases. There is an urgent need to identify individuals with preclinical AD, a 10–20-year period of progressive brain pathology without noticeable cognitive symptoms, for targeted risk reduction. Current tests of AD pathology are either too invasive, specialised or expensive for population-level assessments. Cognitive tests are normal in preclinical AD. Emerging evidence demonstrates that movement analysis is sensitive to AD across the disease continuum, including preclinical AD. Our new smartphone test, TapTalk, combines analysis of hand and speech-like movements to detect AD risk. This study aims to [1] determine which combinations of hand-speech movement data most accurately predict preclinical AD [2], determine usability, reliability, and validity of TapTalk in cognitively asymptomatic older adults and [3], prospectively validate TapTalk in older adults who have cognitive symptoms against cognitive tests and clinical diagnoses of Mild Cognitive Impairment and AD dementia. Methods Aim 1 will be addressed in a cross-sectional study of at least 500 cognitively asymptomatic older adults who will complete computerised tests comprising measures of hand motor control (finger tapping) and oro-motor control (syllabic diadochokinesis). So far, 1382 adults, mean (SD) age 66.20 (7.65) years, range 50–92 (72.07% female) have been recruited. Motor measures will be compared to a blood-based AD biomarker, phosphorylated tau 181 to develop an algorithm that classifies preclinical AD risk. Aim 2 comprises three sub-studies in cognitively asymptomatic adults: (i) a cross-sectional study of 30–40 adults to determine the validity of data collection from different types of smartphones, (ii) a prospective cohort study of 50–100 adults ≥ 50 years old to determine usability and test-retest reliability, and (iii) a prospective cohort study of ~1,000 adults ≥ 50 years old to validate against cognitive measures. Aim 3 will be addressed in a cross-sectional study of ~200 participants with cognitive symptoms to validate TapTalk against Montreal Cognitive Assessment and interdisciplinary consensus diagnosis. Discussion This study will establish the precision of TapTalk to identify preclinical AD and estimate risk of cognitive decline. If accurate, this innovative smartphone app will enable low-cost, accessible screening of individuals for AD risk. This will have wide applications in public health initiatives and clinical trials. Trial registration ClinicalTrials.gov identifier: NCT06114914, 29 October 2023. Retrospectively registered. |
| first_indexed | 2024-04-24T07:14:09Z |
| format | Article |
| id | doaj.art-74f6fbaa4eec4ff48e00b119eaf2c298 |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-04-24T07:14:09Z |
| publishDate | 2024-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-74f6fbaa4eec4ff48e00b119eaf2c2982024-04-21T11:22:33ZengBMCBMC Neurology1471-23772024-04-0124111510.1186/s12883-024-03609-zDevelopment of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuumJane Alty0Lynette R. Goldberg1Eddy Roccati2Katherine Lawler3Quan Bai4Guan Huang5Aidan D Bindoff6Renjie Li7Xinyi Wang8Rebecca J. St George9Kaylee Rudd10Larissa Bartlett11Jessica M. Collins12Mimieveshiofuo Aiyede13Nadeeshani Fernando14Anju Bhagwat15Julia Giffard16Katharine Salmon17Scott McDonald18Anna E. King19James C. Vickers20Wicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaSchool of Information and Communication Technology, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaSchool of Psychological Sciences, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaRoyal Hobart HospitalRoyal Hobart HospitalWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaWicking Dementia Research and Education Centre, University of TasmaniaAbstract Background Dementia prevalence is predicted to triple to 152 million globally by 2050. Alzheimer’s disease (AD) constitutes 70% of cases. There is an urgent need to identify individuals with preclinical AD, a 10–20-year period of progressive brain pathology without noticeable cognitive symptoms, for targeted risk reduction. Current tests of AD pathology are either too invasive, specialised or expensive for population-level assessments. Cognitive tests are normal in preclinical AD. Emerging evidence demonstrates that movement analysis is sensitive to AD across the disease continuum, including preclinical AD. Our new smartphone test, TapTalk, combines analysis of hand and speech-like movements to detect AD risk. This study aims to [1] determine which combinations of hand-speech movement data most accurately predict preclinical AD [2], determine usability, reliability, and validity of TapTalk in cognitively asymptomatic older adults and [3], prospectively validate TapTalk in older adults who have cognitive symptoms against cognitive tests and clinical diagnoses of Mild Cognitive Impairment and AD dementia. Methods Aim 1 will be addressed in a cross-sectional study of at least 500 cognitively asymptomatic older adults who will complete computerised tests comprising measures of hand motor control (finger tapping) and oro-motor control (syllabic diadochokinesis). So far, 1382 adults, mean (SD) age 66.20 (7.65) years, range 50–92 (72.07% female) have been recruited. Motor measures will be compared to a blood-based AD biomarker, phosphorylated tau 181 to develop an algorithm that classifies preclinical AD risk. Aim 2 comprises three sub-studies in cognitively asymptomatic adults: (i) a cross-sectional study of 30–40 adults to determine the validity of data collection from different types of smartphones, (ii) a prospective cohort study of 50–100 adults ≥ 50 years old to determine usability and test-retest reliability, and (iii) a prospective cohort study of ~1,000 adults ≥ 50 years old to validate against cognitive measures. Aim 3 will be addressed in a cross-sectional study of ~200 participants with cognitive symptoms to validate TapTalk against Montreal Cognitive Assessment and interdisciplinary consensus diagnosis. Discussion This study will establish the precision of TapTalk to identify preclinical AD and estimate risk of cognitive decline. If accurate, this innovative smartphone app will enable low-cost, accessible screening of individuals for AD risk. This will have wide applications in public health initiatives and clinical trials. Trial registration ClinicalTrials.gov identifier: NCT06114914, 29 October 2023. Retrospectively registered.https://doi.org/10.1186/s12883-024-03609-zAlzheimer’s diseaseDementiaTapTalkFinger-tappingDiadochokinesisComputer vision |
| spellingShingle | Jane Alty Lynette R. Goldberg Eddy Roccati Katherine Lawler Quan Bai Guan Huang Aidan D Bindoff Renjie Li Xinyi Wang Rebecca J. St George Kaylee Rudd Larissa Bartlett Jessica M. Collins Mimieveshiofuo Aiyede Nadeeshani Fernando Anju Bhagwat Julia Giffard Katharine Salmon Scott McDonald Anna E. King James C. Vickers Development of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuum BMC Neurology Alzheimer’s disease Dementia TapTalk Finger-tapping Diadochokinesis Computer vision |
| title | Development of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuum |
| title_full | Development of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuum |
| title_fullStr | Development of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuum |
| title_full_unstemmed | Development of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuum |
| title_short | Development of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuum |
| title_sort | development of a smartphone screening test for preclinical alzheimer s disease and validation across the dementia continuum |
| topic | Alzheimer’s disease Dementia TapTalk Finger-tapping Diadochokinesis Computer vision |
| url | https://doi.org/10.1186/s12883-024-03609-z |
| work_keys_str_mv | AT janealty developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT lynettergoldberg developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT eddyroccati developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT katherinelawler developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT quanbai developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT guanhuang developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT aidandbindoff developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT renjieli developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT xinyiwang developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT rebeccajstgeorge developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT kayleerudd developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT larissabartlett developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT jessicamcollins developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT mimieveshiofuoaiyede developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT nadeeshanifernando developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT anjubhagwat developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT juliagiffard developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT katharinesalmon developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT scottmcdonald developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT annaeking developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum AT jamescvickers developmentofasmartphonescreeningtestforpreclinicalalzheimersdiseaseandvalidationacrossthedementiacontinuum |